With its versatile and powerful TEMPO epigenomic control platform, Tune Therapeutics is pioneering a new therapeutic modality that can fine-tune any gene network and unlock the full power and potential of regenerative medicine.

With deep experience and a passionate commitment to exploration and innovation, Tune is driving through an inflection point in the history of genetic medicine: from targeting a limited range of rare conditions, to addressing thousands of common and complex diseases for which no curative treatment is available.

Biotechnology

Education

Tune Therapeutics

Charles A. Gersbach

Jason Dean

Kendra Congdon

Tyler Goodwin

Zachary Hale

Georgeta Puscalau

Katherine H.

Michael P. Hefferan

Derek Jantz

Nathaniel Lambert

Iram Khan

Christina Jordan

Glenn Murphy

Luis Sanchez-Perez

Shannon Grace

Ryan Tam

Tune Therapeutics' Board of Directors includes Fyodor Urnov.

Board of Directors

Leadership Team

CEO and Executive Team

Founding Team

Board of Directors

About

Team members

Other teams at Tune Therapeutics

Leadership Team

CEO and Executive Team

Founding Team